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MicroRNAs are increasingly recognized as epigenetic regulators for outcome of
diverse infectious diseases and vaccination efficacy, but little information referring to
this exists for malaria. This study investigates possible effects of both protective
vaccination and P. chabaudi malaria on the miRNome of the liver as an effector against
blood-stage malaria using miRNA microarrays and quantitative PCR. Plasmodium
chabaudi blood-stage malaria takes a lethal outcome in female Balb/c mice, but a
self-healing course after immunization with a non-infectious blood-stage vaccine. The
liver robustly expresses 71 miRNA species at varying levels, among which 65 miRNA
species respond to malaria evidenced as steadily increasing or decreasing expressions
reaching highest or lowest levels toward the end of the crisis phase on day 11 p.i. in
lethal malaria. Protective vaccination does not affect constitutive miRNA expression,
but leads to significant (p < 0.05) changes in the expression of 41 miRNA species,
however evidenced only during crisis. In vaccination-induced self-healing infections, 18
miRNA-species are up- and 14 miRNA-species are down-regulated by more than 50%
during crisis in relation to non-vaccinated mice. Vaccination-induced self-healing and
survival of otherwise lethal infections of P. chabaudi activate epigenetic miRNA-regulated
remodeling processes in the liver manifesting themselves during crisis. Especially,
liver regeneration is accelerated as suggested by upregulation of let-7a-5p, let-7b-5p,
let-7c-5p, let-7d-5p, let-7f-5p, let-7g-5p, let-7i-5p, miR-26a, miR-122-5p, miR30a,
miR27a, and mir-29a, whereas the up-regulated expression of miR-142-3p by more
than 100% is compatible with the view of enhanced hepatic erythropoiesis, possibly at
expense of megakaryopoiesis, during crisis of P. chabaudi blood-stage malaria.
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INTRODUCTION
The World Health Organization has reported about 214 million
new cases of malaria with about 438,000 deaths worldwide in
2015 (WHO, 2015). A vaccine for an effective and reliable anti-
malaria prophylaxis is not yet available, despite enormous efforts
during the last 35 years (Halbroth and Draper, 2015; Hoffman
et al., 2015; Miura, 2016). Until recently, the RTS,S/AS01 has
been regarded as the most advanced vaccine candidate. Indeed,
the European Medicines Agency has approved RTS,S/AS01 for
immunizations of very young children, however the WHO has
not recommended its inclusion in the Expanded Programme of
Immunizations (Birkitt, 2016; Gosling and von Seidlein, 2016).
This points to the urgency of more basic research to uncover
those mechanisms of the host defense, which a vaccine has to
activate to provide protection against malaria.
The experimental malaria P. chabaudi in mice shares several
characteristics with P. falciparum, the most dangerous malaria
species for humans (Longley et al., 2011; Stephens et al.,
2012). It is a convenient model to study blood-stage malaria.
The outcome of P. chabaudi blood-stage malaria is controlled
by genes of the mouse-MHC, the H-2 complex, genes of
the non-H-2 background, and environmental factors such as
testosterone (Wunderlich et al., 1988d). Moreover, there is
a vaccination technique available by which survival of mice,
being naturally susceptible to malaria, can be raised from
0% to over 80% (Wunderlich et al., 1988a; Krücken et al.,
2009). This technique, which uses a non-infectious vaccine
consisting of surface membranes isolated from P. chabaudi-
infected erythrocytes containing parasite-synthesized proteins
(Wunderlich et al., 1988b,c; Fontaine et al., 2012), converts lethal
blood-stage infections to take a self-healing course (Krücken
et al., 2009). Upon challenging with 106 P. chabaudi-parasitized
erythrocytes, all non-vaccinated mice succumb to malaria during
the crisis phase of infection, whereas the majority of vaccinated
mice survive the infections and generate long-lasting immune
mechanisms against homologous re-challenge (Krücken et al.,
2009).
The spleen is currently envisioned as the key effector
organ against blood-stage malaria (Engwerda et al., 2005;
Del Portillo et al., 2012). Indeed, the spleen is equipped
with a unique system to eliminate senescent and aberrant
erythrocytes including P.-infected erythrocytes. However, there
is accumulating evidence that, also the liver, in particular
the erythrophagocytotic Kupffer cells are able to remove
senescent and other aberrant erythrocytes including P.-infected
erythrocytes (Terpstra and van Berkel, 2000; Otogata et al.,
2007; Delic et al., 2010; Lee et al., 2011; Wunderlich et al.,
2014). In self-healing infections of P. chabaudi, it has been
described that the liver dramatically increases its uptake of
injected particles at peak parasitemia and during subsequent
crisis, whereas, concomitantly, the spleen dramatically declines
its uptake of injected particulate material including fluorescently
labeled P. chabaudi-infected erythrocytes (Krücken et al., 2005,
2009). It is therefore rather likely that the liver, rather than
the spleen, massively removes P. chabaudi-infected erythrocytes
from circulation during crisis in vaccination-induced self-healing
infections of P. chabaudi (Wunderlich et al., 2014). Very recently,
the liver has been even described as the primary organ for a
unique mechanism of rapid on-demand erythrocyte disposal
(Theurl et al., 2016).
Current evidence demonstrates that miRNAs are critical for
maintaining phenotype and functionality of the liver (Chen
and Verfaillie, 2014), and that diverse diseases of the liver
are associated with dysregulations in the miRNA signature
(Szabo and Bala, 2013; Bandiera et al., 2015). MicroRNAs are
non-coding single-stranded RNAs of 22 nts in length, which
posttranscriptionally regulate gene expression by affecting both
stability and translation of mRNAs. At least one third of human
genes are estimated to be targeted by miRNAs (He and Hannon,
2004).MicroRNAs are involved in regulating epigenetic networks
within cells and via exosomes between cells (Vyas and Dhawan,
2016). They are increasingly recognized as to be critical for
the outcome of diverse infectious diseases (Bettencourt et al.,
2016; Das et al., 2016; Verma et al., 2016). Also, miRNAs
appear to be critical for efficacy of vaccination (Corral-Fernández
et al., 2016; Shim et al., 2016; Wang et al., 2016). However,
there is still little information available about host miRNAs
in malaria, especially with respect to course and outcome of
malaria infections and vaccination efficacy (Cohen et al., 2015;
Rubio et al., 2016). At least, it is known that miRNAs of the
liver are responsive to blood-stage infections of P. chabaudi
malaria (Delic et al., 2011). The aim of this paper is therefore to
analyze as to whether protective vaccination against P. chabaudi
malaria leads to changes in the overall expression of miRNAs
in the liver during self-healing infections of P. chabaudi in
comparison to lethal infections in non-vaccinated female Balb/c
mice.
MATERIALS AND METHODS
Mice
Balb/c mice were bred under specified pathogen-free conditions.
For the experiments, only female Balb/c mice, approximately
10–14 weeks old, were used. They were housed in plastic cages,
received a standard diet (Woehrlin, Bad Salzuflen, Germany) and
water ad libitum. This study was carried out in strict accordance
with the German law on animal protection. The keeping of
mice and the experimental protocol of the study were officially
approved by the State-controlled Committee on the Ethics of
Animal Experiments and were regularly controlled, without
being previously announced, by the local authorities. All efforts
were made to minimize suffering of mice.
P. chabaudi Malaria
A non-clonal line of P. chabaudi is used in our laboratory since
1982 (Wunderlich et al., 1982), which resembles to P. chabaudi
chabaudi AS as described previously (Wunderlich et al., 2005;
Krücken et al., 2009). Blood-stage infections were routinely
maintained in outbred mice under sterile conditions by weekly
passages of infected blood. Balb/c mice were i.p. challenged
with 106 P. chabaudi-infected erythrocytes. Erythrocytes were
counted in a Neubauer chamber and parasitemia was evaluated
in Giemsa-stained smears from tail blood.
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Vaccination
Mice were vaccinated as performed previously (Krücken et al.,
2009). As a vaccine we have used host cell plasma membranes,
isolated in the form of ghosts from P. chabaudi-parasitized red
blood cells as described elsewhere (Wunderlich et al., 1985, 1987).
Approximately 106 ghosts suspended in 100µl Freund’s complete
adjuvant were injected on week 3 and week 1 before challenge
with 106 P. chabaudi-parasitized erythrocytes (Krücken et al.,
2009). Controls received only the adjuvant.
RNA Isolation
Livers were removed from sacrificed mice, rapidly frozen
in liquid nitrogen and stored at −80◦C until use. Frozen
livers were grounded in a mortar under liquid nirogen and
aliquots were used to isolate total RNA using Trizol (Sigma-
Aldrich). An additional cleaning step was performed by using
the miRNeasy Kit (Qiagen). RNA quality and integrity were
determined using the Agilent RNA 6000 Nano Kit on the
Agilent 2100 Bioanalyzer platform (Agilent Technologies).
RNA was quantified by measuring A260 nm on the ND-1000
Spectrophotometer (NanoDrop Technologies).
Labeling of miRNA
Labeling of the samples was performed as detailed in the “miRNA
Microarray SystemwithmiRNAComplete Labeling andHybKit”
protocol (version 2.4, part number G4170-90011). In brief, 100 ng
of each total RNA sample was used for the labeling step using the
miRNA Complete Labeling and Hyb Kit (Agilent Technologies).
Hybridization of Agilent microRNA
Microarrays
The used Agilent Mouse microRNA Microarrays 8 × 60K
v19 (Design ID 046065) contain 8 arrays per slide and one
array is equipped with probes for detecting 1247 mouse
miRNAs. Hybridization was performed according to the “miRNA
Complete Labeling and Hyb Kit” protocol (version 2.4, part
number G4170-90011) using the miRNA Complete Labeling
and Hyb Kit (Agilent Technologies). In brief, Cy3-labeled RNA
in hybridization buffer was hybridized overnight (20 h, 55◦C)
to the microarrays using Agilent’s recommended hybridization
chamber and oven. Thereafter, themicroarrays were washed once
with the Agilent Gene Expression Wash Buffer 1 for 5min at
room temperature and once by a second wash with preheated
Agilent Gene Expression Wash Buffer 2 (37◦C) for 5min.
Scanning and Data Analysis
Agilent’s Microarray Scanner System G2505C (Agilent
Technologies) was used to detect fluorescence signals of the
hybridized Agilent Microarrays. The Agilent Feature Extraction
Software (FES) 10.7.3.1 was used to read out and process the
microarray image files. For determination of differential miRNA
expression, FES derived output data files were further analyzed
using the GeneSpringGX (Version 12.6) analysis system (Agilent
Technologies). Expression levels were log2 transformed and
given in light units. If a miRNA is absent in the investigated
sample the light units are automatically set by the FES to 0.1
light units, a value of −3.3 (log2 of 0.1) reflects therefore a
non-expressed miRNA. Only those values were used with >100
lights units representing robustly expressed miRNAs. A heatmap
was generated to visualize the expression levels of each miRNA
(Spotfire, TIBCO Software Inc., Palo Alto, USA). The row and
column dendrograms were clustered with the unweighted pair
group method with arithmetic mean and Euclidean distance
measure. Significant malaria-responsive and/or protective
vaccination effects on miRNA expression were assessed using
2-way ANOVA. MicroRNAs with at least 2-fold deregulation
and a P < 0.05 in any group-wise comparison were considered
as to be differentially expressed. P values were corrected using
Benjamini-Hochberg method for multiple testing (Benjamini
and Hochberg, 1995). Raw data are publicly available at the
EMBL-EBI Array Express repository (Array Express accession
number: E-MTAB-5301).
Quantitative Real-time PCR
TaqMan R© MicroRNA Reverse Transcription Kit (Applied
Biosystems) and MegaplexTM RT Primers, Rodent Pool A
and B (Applied Biosystems) were used to reverse transcribe
miRNAs. Reactions were performed in triplicates using the
following TaqMan R© MicroRNA Assays (Applied Biosystems):
let-7a-5p (assay ID: 00377), let-7c-5p (assay ID: 00379), miR-
122-5p (assay ID: 002245), miR-142-3p (assay ID: 000464),
miR-29b-3p (assay ID: 000413), miR-30c-5p (assay ID:
000419), miR-669n (assay ID: 197143_mat), miR-709 (assay ID:
001644), miR-92-3p (assay ID: 000430), miR-126-3p (assay ID:
002228). PCR reactions were performed with the TaqMan R©
gene expression master mix (Life Technologies) according
manufacturer’s protocol on a 7900HT real-time PCR System.
The miRNA expression analysis was run on a SDS7900HT real
time PCR system; raw Ct values were calculated using the SDS
software v2.4 with automatic baseline and threshold settings.
U6 snRNA (assay ID: 001973) was used for normalization. Fold
change of expression was calculated using the comparative Ct
method (2−11ct) (Livak and Schmittgen, 2001). Data sets were
analyzed for statistical significance using two-tailed unpaired
heteroskedastic Student’s t-test.
RESULTS
To explore possible changes of hepatic miRNome by protective
vaccination and/or subsequent challenge infections with
P. chabaudi blood-stage malaria, microarrays were used to
analyze miRNA expression in livers from vaccination-protected
(V) and non-protected non-vaccinated mice (N) before infection
on day 0 p.i. (Vd0, Nd0), and during different phases of the
infections, i.e., at the beginning of infection on day 1 p.i. (Vd1,
Nd1), during the mid-precrisis phase on day 4 p.i. (Vd4, Nd4), at
peak parasitemia on day 8 p.i. (Vd8, Nd8), and toward the end
of the crisis phase on day 11 p.i. (Vd11, Nd11). The parasitemia
is about the same in self-healing infections of vaccination-
protected mice and in lethal infections of non-protected mice
(Figure 1). Only at peak parasitemia, there is a significant lower
parasitemia in self-healing infections (Figure 1). Figure 2 shows
the heat map of miRNA expression profiles during self-healing
and lethal infections in vaccination-protected and non-protected
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FIGURE 1 | Course of parasitemia during self-healing infections of
P. chabaudi in vaccination-protected Balb/c mice and lethal infections
in non-vaccinated mice. Values represent means determined from three
mice whose livers were taken to analyze miRNA expression. Bars represent
half SD and star indicates significant difference (p < 0.01).
mice, respectively. The profiles on day 0, 1, and 4 p.i. cluster
separately from those on day 8 and 11 p.i., respectively, which
are closer together.
Among the overall detectable 1247 miRNA species on a given
array, 71 miRNA species are found to be robustly expressed
(>100 light units) in the liver of both vaccinated and non-
vaccinated mice. The most abundant expressions show the
miRNAs miR-122-5p, miR-6366, miR-3963 and miR-5100, while
relatively low expression is observed for the miRNAs miR-1196-
5p, miR-468-3p and miR-669n. None of these miRNA species
is affected by protective vaccination per se, evidenced as the
expressions of the 71 miRNAs in vaccinated non-infected mice
in comparison with the corresponding constitutive expressions
in non-vaccinated mice. Upon infection with P. chabaudi,
however, 65 miRNA species change their expression pattern, and
41 miRNA species out of the 65 malaria-responsive miRNAs
significantly (p < 0.05) differ with respect to their expression
levels in the liver between vaccinated and non-vaccinated mice.
However, this difference is only evidenced toward the end of the
crisis phase on day 11 p.i..
The lethal outcome of P. chabaudi malaria is associated with
either increasing or decreasing expressions of miRNAs in the
liver during the infections, reaching their minimal or maximal
expression levels toward the end of the crisis phase on day 11
p.i. (cf. also Figures 3, 4). Decreasing expressions reveal the
18 miRNA species miR-122-5p, miR-142-3p, miR-148-3p, miR-
26a-5p, miR-27a-5p, miR-29b-3p, miR-2861, miR30a/c-5p, miR-
3968, miR-5097, and seven members of the let miRNA family
(Figure 3), whereas increasing expressions occur for the 14
miRNAsmiR-188-5p, miR1187, miR-1196-5p, miR-211-3p, miR-
32-3p, miR-3082-5p, miR-3960, miR-466i-5p, miR-468-3p, miR-
574-5p, miR-669n, miR-709, mir-5126, and miR-6538 (Figure 4).
In vaccination-induced self-healing infections, however, the
decreasing expression of the 18 miRNAs is stopped or even
slightly turned to be up-regulated only by the end of crisis
(Figure 3), whereas the increasing expression of the 14 miRNA
species is impaired or even turned down (Figure 4). The up- or
down-regulated expressions amount to more than 50% at the
end of the crisis phase between vaccination-induced self-healing
infections and lethal infections in non-vaccinated mice.
Tables 1, 2 summarize the annotated functions of the 18 and
14 miRNA species, whose expression is either up- or down-
regulated in the liver of vaccination-protected mice toward the
end of the crisis phase of P. chabaudi infections in relation
to non-vaccinated mice, respectively. Remarkably, all the seven
up-regulated members of the let-7 miRNA family are known to
be involved in liver regeneration.
To further substantiate these differences in miRNA expression
toward the end of the crisis phase, we have also performed
quantitative PCR of arbitrarily selected miRNAs. Figure 5 shows
that the miRNAs let-7a-5p, let-7c-5p, miR-122-5p, miR-142-3p,
miR-29b-3p, and miR-30c-5p are up-regulated and the miRNA
species miR-669n and miR-709 are down-regulated in livers
of vaccination-induced self-healing infections on day 11 p.i. in
comparison to lethal infections in non-vaccinated mice, thus
confirming our microarray analyses. By contrast, the expressions
of the malaria-responsive miR-92-3p and miR-126-3p are not
significantly affected by infections, as it was also found by
microarrays.
DISCUSSION
This is the first study providing evidence that protective
vaccination against blood-stage malaria of P. chabaudi leads
to changes in the expression of distinct miRNA species in the
liver during subsequent homologous challenge infections. These
changes, however, are evidenced only toward the end of the
crisis phase on day 11 p.i. in relation to lethal infections in non-
vaccinated mice. Lethal malaria induces increasing expressions
of 18 miRNA species and decreasing expressions of 14 miRNA
species during the precrisis phase reaching highest and lowest
expression levels toward the end of the crisis phase. In vaccinated
mice, however, the course of the decreasing and increasing
expressions of the 18 and 14 miRNA species, respectively, is
apparently stopped at peak parasitemia and even partly reversed
during crisis, resulting in changes by more than 50 % in relation
to non-vaccineted mice toward the end of the crisis phase.
This suggests that vaccination-induced self-healing infections of
P. chabaudi blood-stage malaria are associated with a remodeling
of miRNA-controlled processes in the liver of Balb/c mice, which
otherwise would lead to a lethal outcome of the infections during
crisis.
Such a remodeling is presumably associated with an
accelerated liver regeneration. Indeed, seven members of the let-
7 miRNA family, found here to be up-regulated in the liver of
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FIGURE 2 | Heatmap of expression levels of miRNAs in the liver of non-vaccinated (N) and vaccinated (V) mice infected with P. chabaudi on days 0, 1,
4, 8, and 11 p.i. Expression levels for each sample were hierarchically clustered. Log2 transformed expression levels range from −4 to 14 indicated by blue and red
color, respectively.
vaccination-protected mice during crisis, have been all described
to be involved in liver regeneration by targeting mRNAs of dicer
and trbp (Forman et al., 2008; Shu et al., 2011). Also, the mir-
26a up-regulated during crisis is known to be involved in liver
regeneration and hepatocyte proliferation (Zhou et al., 2016).
Moreover, the down-regulated expression levels of miR-1187
may reflect diminished hepatocyte apoptosis through targeting
casp-8 (Yu et al., 2012). Furthermore, the down-regulated
levels of miR-669n during crisis may conceivably contribute to
accelerated liver regeneration by dampening malaria-induced
Kupffer cell activation (Long et al., 2015). All these data
support the view that liver regeneration may be accelerated in
vaccination-protected mice during the crisis phase of self-healing
infections of otherwise lethal P. chabaudi malaria. Accelerated
liver regeneration in vaccinated mice is presumably not a direct
effect of vaccination, but rather it may be associated with the
process of self-healing, i.e., it may be an indirect consequence
of the vaccination-induced conversion of lethal to self-healing
infections of P. chabaudi.
Accelerated liver regeneration may contribute to overcome
dysfunctions of the liver, presumably due to injuries induced
by the P. chabaudi blood-stage infections. Indeed, the acute
phase of P. chabaudi malaria has been described to be associated
with pathological damages and heavy injuries in the liver with
distant effects on other organs, as e.g., hepatoencephalopathy
(Wunderlich et al., 2005; Delic et al., 2010). Even human patients
suffering from malaria with P. falciparum and P. vivax have been
shown to be associated with massive dys-functions of the liver
(Ananad et al., 1992; Kochar et al., 2003; Nautyal et al., 2005;
Rupani and Amarapurkar, 2009). Moreover, it is known that
pathogenesis and diseases of the liver are in general associated
with dys-regulated expressions of diverse miRNAs (Szabo and
Bala, 2013; Chen and Verfaillie, 2014; Bandiera et al., 2015;
Murakami and Kawada, 2016). For instance, injuries of the
liver in HIV/HCV patients suffering from necroinflammation
and portal hypertension have been recently reported to cause
elevated levels of themiR-122, themost abundant miRNA species
in the liver (Jansen et al., 2015). Our data, however, reveal
continuously decreasing levels of miR-122-5p in the liver of both
vaccinated and non-vaccinated mice during the precrisis phase
of self-healing and lethal P. chabaudi infections, respectively.
Only during the crisis phase, vaccination-protected mice exhibit
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FIGURE 3 | Time course of relative miRNA expression with increased levels in the liver of vaccinated mice toward the end of the crisis phase of
P. chabaudi infections in comparison to non-vaccinated mice. Relative miRNA expression was normalized to the mean constitutive expression of the
corresponding miRNAs. Open circles are values of vaccinated mice and filled circles are those of non-vaccinated mice. Values are given in mean ± SD. Significant
differences are indicated by *(P < 0.05).
elevated levels of miR-122-5p, whereas the corresponding levels
further decrease in non-vaccinated mice with lethal infections.
Similar courses of miRNA expression levels are here found for
miR-30a known to be involved in manifestation and resolution
of liver fibrosis (Roy et al., 2015), for miR-27a described to be
involved in fibrosis (Cui et al., 2016), and for mir-29b known
to suppress transcription of genes encoding for extracellular
matrix proteins (cf. Table 1) (Roderburg et al., 2011; Lambrecht
et al., 2015; Kitano and Bloomston, 2016). Thus, the dys-
regulations of these different miRNA species may presumably
due to the liver injuries induced by P. chabaudi blood-stage
malaria occurring during precrisis in both vaccination-protected
and non-vaccinated mice. However, the up-regulated levels
of mir-122-5p, miR-30a, mir-27a, and miR-29, observed in
vaccination-protected mice during crisis, may contribute to
the accelerated liver regeneration suggested to occur in these
mice.
Moreover, the present study shows that the expression level
of mir-142-3p is significantly up-regulated during crisis by
more than 100% in the liver of vaccinated mice as compared
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FIGURE 4 | Time course of relative miRNA expression of significantly decreased hepatic miRNA levels in vaccinated mice toward the end of the crisis
phase of P. chabaudi infections compared to non-vaccinated mice. Relative miRNA expression was normalized to the mean constitutive expression levels of
the corresponding miRNAs. Open circles, vaccinated mice. Filled circles, non-vaccinated mice. Values represent means ± SD. Significant differences are indicated by
*(P < 0.05).
with non-vaccinated mice, i.e., this percental difference during
crisis is by far higher than those found for all other malaria-
responsive miRNA species in the liver. Recent evidence indicates
that the miRNA-142 locus is important for the regulation
of macrophage-related processes, as e.g., macrophage and
dendritic cell differentiation (Fordham et al., 2015), regulation
of cell migration (Kim et al., 2015), control of profibrogenic
macrophage program (Su et al., 2015), role in colony-stimulating
factor 1-induced monocyte differentiation into macrophages
(Lagrange et al., 2013), prevention of macrophage differentiation
during cancer-induced myelopoiesis (Sonda et al., 2013). The
relevance of these data for the liver of vaccinated mice remains
to be shown. Currently, however, the most unequivocal evidence
demonstrates that mir-142-3p is critical for megakaryopoiesis
(Chapnik et al., 2014). The miRNA-142-3p stringently controls
specific cytoskeletal rearrangements required for maturation and
function of megakaryocytes, and genetic deletion of miR-142-3p
results in impaired megakaryocyte ablation, cytoskeletal dys-
integrity, abnormal proplatelet formation and thrombocytopenia
(Chapnik et al., 2014). In accordance, thrombocytopenia also
occurs in experimental malaria including P. chabaudi malaria
(Watier et al., 1992; Piguet et al., 2000, 2002; Gramaglia et al.,
2005) and even represents a severe complication in human
malaria caused by P. vivax and P. falciparum (Ansari et al., 2009;
Lacerda et al., 2011; Gill et al., 2013; Gupta et al., 2013). Thus,
our data showing up-regulation of mir-142-3p may suggest that
protective vaccination affects hepatic megakaryopoiesis induced
by P. chabaudi blood-stage malaria during crisis.
On the other hand, however, there is evidence that miR-
142-3p is also involved in the regulation of erythropoiesis
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TABLE 1 | Increased hepatic miRNA expression in vaccinated mice infected with P. chabaudi on day 11 p.i. (Vd11) compared to non-vaccinated mice
infected with P. chabaudi on day 11 p.i. (Nd11).
miRNA name % increase
Vd11 vs. Nd11
Function PMID
let-7a +50 Up-regulated during early phase of liver regeneration 21574170, 18812516
let-7b +50 Up-regulated during early phase of liver regeneration 21574170, 18812516
let-7c +50 Up-regulated during early phase of liver regeneration 21574170, 18812516
let-7d +51 Up-regulated during early phase of liver regeneration 21574170, 18812516
let-7f +51 Up-regulated during early phase of liver regeneration 21574170, 18812516
let-7g +51 Up-regulated during early phase of liver regeneration 21574170, 18812516
let-7i +57 Up-regulated during early phase of liver regeneration 21574170, 18812516
miR-122-5p +60 Abundantly expressed in liver; involved in cholesterol biosynthesis pathway; binds to the
HCV genome and enhances viral translation and replication
16258535,25574453, 16141076
miR-142-3p +121 Orchestrates network of actin cytoskeleton during megakaryopiesis 24859754
miR-148a-3p +81 miR-148a-3p downregulates Met/Snail signaling pathway and thus inhibits the epithelial to
mesenchymal transition (EMT)
23532995
miR-26a-5p +63 Involved in liver regeneration and hepatocyte proliferation; miR-26a expression reduced
M-CSF expression and recruitment of macrophages in HCC
26818545, 26021873
miR-27a-3p +71 Involved in lung fibrosis 26600197
miR-29b-3p +61 Members of the miR-29 family are downregulated in HSCs in response to TNF and TGF-β
signaling and suppress the transcription of ECM genes like collagen-1α1
20890893
miR-2861 +52 Important physiological role in osteoblast differentiation and contributes to osteoporosis via
its effect on osteoblasts
19920351
miR-30a-5p +52 Members of a network of miRNAs modifying the TGF-β-dependent regulation of extracellular
matrix-related genes in HSCs in the manifestation and resolution of liver fibrosis
26120970
miR-30c-5p +127 Members of a network of miRNAs modifying the TGF-β-dependent regulation of extracellular
matrix-related genes in HSCs in the manifestation and resolution of liver fibrosis
26120970
miR-3968 +96 Unknown
miR-5097 +98 Unknown
TABLE 2 | Decreased hepatic miRNA expression in vaccinated mice infected with P. chabaudi on day 11 p.i. (Vd11) compared to non-vaccinated mice
infected with P. chabaudi on day 11 p.i. (Nd11).
miRNA name % Increase Vd11 vs. Nd11 Function PMID
miR-188-5p −65 Acts as a tumor suppressor in prostate caner 25714029
miR-1187 −54 Involved in hepatocyte apoptosis 22266786
miR-1196-5p −37 Unknown
miR-211-3p −55 lncRNA-uc002kmd.1 regulates CD44 as a molecular decoy for miR211-3p 26974151
miR-32-3p −54 Acts a a tumor suppressor in NSCLC 26229485
miR-3082-5p −55 Unknown
miR-3960 −56 miR-3960 regulated cellular growth and proliferation through a regulatory feedback
loop with miR-2861, respnse to oxidative stress
21324897, 26539117
miR-466i-5p −49 Unknown
miR-468-3p −57 Unknown
miR-574-5p −53 Oncogene in various cancer types, incl. SCLC 26587830
miR-669n −55 Involved in control of LPS-induced macrophage activation 26807181
miR-709 −35 miR-709 may positively regulate invasion and metastasis of HCC through
targeting GPC5
25818666
miR-5126 −43 Unknown
miR-6538 −53 Unknown
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FIGURE 5 | Quantitative PCR of different miRNA species in the liver of vaccination-protected Balb/c mice infected with P. chabaudi on day 11 p.i.
(Vd11) in relation to expression on day 0 p.i. (Vd0). Corresponding analyses for non-vaccinated mice (Nd11 vs. Nd0). Bars indicate half SD, (*) significant
differences (p < 0.01).
(Muhseen and Abbood, 2014). Erythropoiesis in turn is
tightly coupled with megakaryopoiesis. Both erythropoiesis
and megakaryopoiesis are controlled by the two transcription
factors GATA1 and GFI1b (Fatica et al., 2006; Crispino and
Weiss, 2014). Moreover, both megakaryocytic and erythroid
cells are derived from common myeloid precursors (Fatica
et al., 2006), and there exist even bipotent progenitor stem
cells generating both erythroid and magakaryoctic cells (Debili
et al., 1996; Papayannopoulou et al., 1996; Papayannopoulou
and Kaushansky, 2016). However, there is also information
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available that erythropoiesis is enhanced at the expense
of megakaryopoiesis (Bianchi et al., 2015). Under identical
experimental conditions as described here, Al-Quraishy et al.
(2016) have recently found that protective vaccination augments
P. chabaudi-induced extramedullary hepatic erythropoiesis. It
appears therefore plausible to assume that the up-regulation of
mir-142-3p observed here during crisis is involved in enhanced
erythropoiesis at the expense of megakaryopoiesis in the liver
of vaccination-induced self-healing infections of P. chabaudi
malaria (Al-Quraishy et al., 2016).
Collectively, our data suggest that vaccination-induced self-
healing and survival of otherwise lethal blood-stage infections
of P. chabaudi malaria activates epigenetic miRNA-regulated
mechanisms in the liver, which accelerate liver regeneration
and enhance hepatic erythropoiesis, possibly at the expense
of megakaryopoiesis, during crisis of P. chabaudi blood-stage
malaria.
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